malasma
Conditions
Interventions
1) Commencement of induction therapy: Tranexamic acid (750-1,500 mg/day) in two divided doses administered in the morning and evening every day for 8 weeks. When sufficient improvement of chloasma is
Sponsors
Non-Profit Organization Health Institute Research of Skin
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Typical patients with chloasma with clear pigmentations aged 20 years old or older 2) Patients who voluntarily provided written informed consent after receiving an explanation of the details of the study
Exclusion criteria
Exclusion criteria: 1) Patients receiving laser toning for chloasma or with experience of such treatment 2) Patients with a history of rheumatism or administration of a gold drug, and those receiving an iron preparation 3) Patients who have or are suspected to have a precancerous lesion or a malignant tumor 4) Patients with photosensitivity and those receiving a drug to enhance photosensitivity 5) Patients who had received treatment with gold string 6) Patients with cardiac disease (serious heart disease or use of a cardiac pacemaker) 7) Patients with hemorrhagic disease or those receiving an anticoagulant (bayaspirin, warfarin, etc.) 8) Patients with possible delayed wound healing (diabetes, connective tissue disease, etc.) 9) Patients with skin disease other than chloasma at irradiated sites 10) Patients with hypersensitive skin (hives, atopic dermatitis, allergic diathesis, etc.) 11) Patients with inflammation at the sites of chloasma 12) Patients receiving hormone replacement therapy 13) Patients who have taken a steroid preparation for a long period of time 14) Pregnant women, those who may be pregnant, lactating women, and women who hope to become pregnant during the study period 15) Patients who may be highly exposed to sunlight through repeated daily daytime outdoor sports activities 16) Patients with sunburnt skin or with the possibility of sunburn after treatment 17) Patients participating in another clinical study at the start of this study 18) Patients with a history of serious disease 19) Other patients who were considered inappropriate to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of pigmentation when luminosity is changed, using a skin tone color scale | — |
Countries
Japan
Contacts
Public ContactNaomi Kanazawa
EBC&M LLC. Project planning & Development department
Outcome results
None listed